Pfenex Company Profile (NYSEMKT:PFNX)

About Pfenex (NYSEMKT:PFNX)

Pfenex logoPfenex Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). Its next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. Its product candidates are enabled by its protein production platform, Pfenex Expression Technology. It is also developing Px563L, an anthrax vaccine candidate, and Px533 as a prophylactic vaccine candidate against malaria infection.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:PFNX
  • CUSIP: N/A
  • Web:
  • Market Cap: $74.35 million
  • Outstanding Shares: 23,528,000
Average Prices:
  • 50 Day Moving Avg: $3.61
  • 200 Day Moving Avg: $4.58
  • 52 Week Range: $2.95 - $11.35
  • Trailing P/E Ratio: 50.48
  • Foreward P/E Ratio: -1.27
  • P/E Growth: -0.04
Sales & Book Value:
  • Annual Revenue: $60.14 million
  • Price / Sales: 1.24
  • Book Value: $2.54 per share
  • Price / Book: 1.24
  • EBIDTA: $3.29 million
  • Net Margins: -406.87%
  • Return on Equity: -75.61%
  • Return on Assets: -57.77%
  • Average Volume: 159,478 shs.
  • Beta: 4.65
  • Short Ratio: 0.6

Frequently Asked Questions for Pfenex (NYSEMKT:PFNX)

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "PFNX."

How were Pfenex's earnings last quarter?

Pfenex Inc (NYSEMKT:PFNX) issued its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.52) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.46) by $0.06. The business earned $3.03 million during the quarter, compared to the consensus estimate of $3.10 million. Pfenex had a negative return on equity of 75.61% and a negative net margin of 406.87%. Pfenex's revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter last year, the company earned ($0.43) EPS. View Pfenex's Earnings History.

When will Pfenex make its next earnings announcement?

Pfenex is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Pfenex.

Who are some of Pfenex's key competitors?

Who are Pfenex's key executives?

Pfenex's management team includes the folowing people:

  • Evert B. Schimmelpennink, President, Chief Executive Officer, Secretary, Director
  • Paul A. Wagner Ph.D., Chief Financial Officer
  • Patricia Lady CPA, Chief Accounting Officer
  • Hubert C. Chen M.D., Chief Medical Officer
  • Patrick K. Lucy, Chief Business Officer
  • Steven S. Sandoval Sr., Chief Manufacturing Officer
  • Robin D. Campbell Ph.D., Independent Director
  • Dennis M. Fenton Ph.D., Independent Director
  • Phillip M. Schneider, Independent Director
  • John M. Taylor III, Independent Director

Who owns Pfenex stock?

Pfenex's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (11.40%), Dow Chemical Co. DE (7.55%), Sanders Morris Harris LLC (3.18%), AWM Investment Company Inc. (2.39%), Vanguard Group Inc. (2.10%) and FMR LLC (1.39%). Company insiders that own Pfenex stock include Bertrand C Liang, Chemical Co /De/ Dow, Henry W Jr Talbot, Jason Grenfell-Gardner, Patricia Lady, Patrick K Lucy and Signet Healthcare Partners Acc. View Institutional Ownership Trends for Pfenex.

Who sold Pfenex stock? Who is selling Pfenex stock?

Pfenex's stock was sold by a variety of institutional investors in the last quarter, including AWM Investment Company Inc., Northern Trust Corp, Franklin Resources Inc., TIAA CREF Investment Management LLC, Vanguard Group Inc., Numeric Investors LLC, Bank of New York Mellon Corp and FMR LLC. Company insiders that have sold Pfenex stock in the last year include Patricia Lady, Patrick K Lucy and Signet Healthcare Partners Acc. View Insider Buying and Selling for Pfenex.

Who bought Pfenex stock? Who is buying Pfenex stock?

Pfenex's stock was bought by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, C WorldWide Group Holding A S, AJO LP, Municipal Employees Retirement System of Michigan, Dimensional Fund Advisors LP, Legal & General Group Plc, Goldman Sachs Group Inc. and Susquehanna International Group LLP. View Insider Buying and Selling for Pfenex.

How do I buy Pfenex stock?

Shares of Pfenex can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfenex's stock price today?

One share of Pfenex stock can currently be purchased for approximately $3.16.

MarketBeat Community Rating for Pfenex (NYSEMKT PFNX)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  168
MarketBeat's community ratings are surveys of what our community members think about Pfenex and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pfenex (NYSEMKT:PFNX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Pfenex (NYSEMKT:PFNX)
DateFirmActionRatingPrice TargetDetails
9/8/2017William BlairReiterated RatingOurperformView Rating Details
8/9/2016MizuhoLower Price TargetBuy$22.00 -> $18.00View Rating Details
5/24/2016Barclays PLCLower Price TargetOverweight$28.00 -> $14.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$25.00 -> $22.00View Rating Details
(Data available from 9/21/2015 forward)


Earnings History for Pfenex (NYSEMKT:PFNX)
Earnings by Quarter for Pfenex (NYSEMKT:PFNX)
Earnings History by Quarter for Pfenex (NYSEMKT PFNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.56)N/AView Earnings Details
8/9/2017Q2 2017($0.46)($0.52)$3.10 million$3.03 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.57)($0.43)$2.50 million$2.80 millionViewListenView Earnings Details
3/15/2017Q4 2016($0.66)($0.45)$2.50 million$5.47 millionViewN/AView Earnings Details
11/9/2016Q316($0.56)$1.46$3.18 million$48.82 millionViewListenView Earnings Details
8/8/2016Q216($0.47)($0.43)$2.55 million$3.10 millionViewN/AView Earnings Details
5/9/2016Q116($0.45)($0.35)$2.35 million$2.76 millionViewN/AView Earnings Details
3/10/2016Q415($0.59)($0.37)$2.56 million$3.30 millionViewListenView Earnings Details
11/13/2015Q315($0.46)($0.33)$2.05 million$2.06 millionViewListenView Earnings Details
8/13/2015Q215($0.39)($0.27)$2.07 million$2.30 millionViewListenView Earnings Details
5/14/2015Q115($0.24)($0.29)$2.10 million$2.00 millionViewListenView Earnings Details
3/16/2015Q4($0.20)($0.18)$2.05 million$2.02 millionViewN/AView Earnings Details
11/13/2014Q3($0.25)($0.16)$2.13 million$2.80 millionViewN/AView Earnings Details
8/29/2014($0.15)($1.67)$1.75 million$3.27 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Pfenex (NYSEMKT:PFNX)
Current Year EPS Consensus Estimate: $-2.09 EPS
Next Year EPS Consensus Estimate: $-2.48 EPS


Dividend History for Pfenex (NYSEMKT:PFNX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Pfenex (NYSEMKT:PFNX)
Insider Trades by Quarter for Pfenex (NYSEMKT:PFNX)
Institutional Ownership by Quarter for Pfenex (NYSEMKT:PFNX)
Insider Trades by Quarter for Pfenex (NYSEMKT:PFNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/12/2017Jason Grenfell-GardnerDirectorBuy10,000$4.51$45,100.00View SEC Filing  
5/16/2017Patricia LadyInsiderSell2,000$4.78$9,560.00View SEC Filing  
1/6/2017Signet Healthcare Partners AccMajor ShareholderSell400$9.50$3,800.00View SEC Filing  
1/5/2017Signet Healthcare Partners AccMajor ShareholderSell7,710$9.50$73,245.00View SEC Filing  
12/29/2016Signet Healthcare Partners AccMajor ShareholderSell24,104$9.66$232,844.64View SEC Filing  
12/27/2016Signet Healthcare Partners AccMajor ShareholderSell104,600$9.58$1,002,068.00View SEC Filing  
12/22/2016Signet Healthcare Partners AccMajor ShareholderSell10,896$9.61$104,710.56View SEC Filing  
11/21/2016Patricia LadyInsiderSell2,000$9.87$19,740.00View SEC Filing  
11/15/2016Patrick K. LucyInsiderSell5,000$10.04$50,200.00View SEC Filing  
8/18/2016Patricia LadyInsiderSell2,000$9.42$18,840.00View SEC Filing  
5/24/2016Patricia LadyCAOSell2,000$6.52$13,040.00View SEC Filing  
5/24/2016Patricia LadyCAOSell2,000$6.52$13,040.00View SEC Filing  
12/15/2015Chemical Co /De/ DowMajor ShareholderSell600,000$11.75$7,050,000.00View SEC Filing  
12/3/2015Patrick K LucyInsiderSell1,500$14.15$21,225.00View SEC Filing  
12/1/2015Bertrand C. LiangCEOSell5,000$14.88$74,400.00View SEC Filing  
12/1/2015Henry W Jr. TalbotVPSell2,000$15.08$30,160.00View SEC Filing  
11/18/2015Patricia LadyCAOSell2,000$14.05$28,100.00View SEC Filing  
11/4/2015Patrick K. LucyinsiderSell1,500$17.54$26,310.00View SEC Filing  
11/2/2015Bertrand C LiangCEOSell5,000$18.01$90,050.00View SEC Filing  
10/2/2015Patrick K LucyInsiderSell1,500$14.98$22,470.00View SEC Filing  
10/1/2015Bertrand C LiangCEOSell5,000$14.78$73,900.00View SEC Filing  
9/3/2015Patricia LadyCAOSell2,000$20.48$40,960.00View SEC Filing  
9/3/2015Patrick K LucyInsiderSell1,500$20.91$31,365.00View SEC Filing  
9/1/2015Bertrand C. LiangCEOSell5,000$21.02$105,100.00View SEC Filing  
7/6/2015Patrick K LucyInsiderSell1,500$19.17$28,755.00View SEC Filing  
7/1/2015Bertrand C LiangCEOSell5,000$19.63$98,150.00View SEC Filing  
6/3/2015Patrick K LucyInsiderSell1,500$20.08$30,120.00View SEC Filing  
6/1/2015Bertrand C LiangCEOSell5,000$18.70$93,500.00View SEC Filing  
5/4/2015Patrick K LucyInsiderSell1,500$13.25$19,875.00View SEC Filing  
5/1/2015Bertrand C LiangCEOSell5,000$13.49$67,450.00View SEC Filing  
4/29/2015Chemical Co /De/ DowMajor ShareholderSell2,232,233$14.57$32,523,634.81View SEC Filing  
4/29/2015James C GaleDirectorSell1,907,767$14.57$27,796,165.19View SEC Filing  
4/2/2015Patrick K LucyInsiderSell1,500$17.62$26,430.00View SEC Filing  
4/1/2015Bertrand C LiangCEOSell5,000$15.27$76,350.00View SEC Filing  
3/4/2015Patrick K LucyInsiderSell1,500$14.36$21,540.00View SEC Filing  
7/29/2014Signet Healthcare Partners AccMajor ShareholderSell380,867$0.31$118,068.77View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Pfenex (NYSEMKT:PFNX)
Latest Headlines for Pfenex (NYSEMKT:PFNX)
DateHeadline logoPfenex To Present at the Cantor Fitzgerald Global Healthcare Conference on September 27th, 2017 - September 20 at 7:38 AM logoCANbridge Life Sciences Appoints Chief Business Officer Will Head First US Office - September 13 at 7:46 AM logoPfenex Inc (PFNX) Rating Reiterated by William Blair - September 8 at 11:30 AM logoPfenex Announces Management Changes - September 8 at 7:07 AM logoPfenex Inc (PFNX) Downgraded by ValuEngine to Strong Sell - September 2 at 6:20 PM logoPfenex To Present at the 19th Annual Rodman and Renshaw Global Investment Conference on September 12th, 2017 - August 29 at 6:36 AM logoZacks Investment Research Upgrades Pfenex Inc (PFNX) to "Hold" - August 26 at 6:58 AM logoPfenex To Present at the 6th Annual Liolios Gateway Conference on September 6th, 2017 - August 24 at 10:59 AM logoPfenex's (NYSEMKT:PFNX) "Outperform" Rating Reiterated at William Blair - August 11 at 4:00 PM logoPfenex Reports Second Quarter 2017 Results and Provides Business Update - August 10 at 6:45 AM logoEdited Transcript of PFNX earnings conference call or presentation 9-Aug-17 8:30pm GMT - August 10 at 6:45 AM logoPfenex Inc (NYSEMKT:PFNX) Announces Earnings Results, Misses Expectations By $0.06 EPS - August 9 at 9:40 PM logoPfenex (PFNX) Names Eef Schimmelpennink as CEO - August 4 at 6:58 AM logoPfenex Names Eef Schimmelpennink Chief Executive Officer - August 3 at 6:54 AM logoPfenex Inc (NYSEMKT:PFNX) Scheduled to Post Earnings on Wednesday - August 2 at 7:32 AM logoValuEngine Downgrades Pfenex Inc (PFNX) to Sell - August 2 at 12:22 AM logoPfenex To Report Second Quarter 2017 Results and Provide Business Update on Wednesday, August 9, 2017 - July 26 at 6:21 AM logoPfenex Inc (PFNX) Rating Lowered to Hold at Zacks Investment Research - July 15 at 12:28 PM logoETFs with exposure to Pfênex, Inc. : July 13, 2017 - July 14 at 7:24 AM logoETFs with exposure to Pfênex, Inc. : June 26, 2017 - June 27 at 7:16 AM logoPfenex Inc (PFNX) Stock Rating Reaffirmed by William Blair - June 26 at 8:34 AM logoInsider Buying: Pfenex Inc (PFNX) Director Acquires 10,000 Shares of Stock - June 12 at 7:52 PM logoPfenex to Present at the 2017 JMP Healthcare Conference - June 8 at 9:13 AM logoPfenex Inc (PFNX) Downgraded by ValuEngine to Sell - June 3 at 3:14 PM logoETFs with exposure to Pfênex, Inc. : June 2, 2017 - June 2 at 9:42 PM logoPfênex, Inc. :PFNX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 1, 2017 - June 1 at 8:00 PM logoEdited Transcript of PFNX earnings conference call or presentation 8-May-17 8:30pm GMT - May 9 at 11:09 AM logoPfenex Inc (PFNX) Issues Earnings Results - May 9 at 9:56 AM logoPfenex Reports First Quarter 2017 Results and Provides Business Update - May 8 at 6:36 PM logoPfenex (PFNX) Getting Favorable Press Coverage, Analysis Finds - April 29 at 6:33 PM logoPfenex (PFNX) Receiving Positive Media Coverage, Report Finds - April 25 at 1:53 PM logoPfenex To Report First Quarter 2017 Results and Provide Business Update on Monday, May 8, 2017 - April 24 at 4:38 PM logoETFs with exposure to Pfênex, Inc. : April 13, 2017 - April 13 at 6:59 PM logoWilliam R. Rohn Announces Plans To Retire As Chairman And Board Member - March 31 at 7:20 PM logoPFENEX INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits - March 31 at 7:20 PM logoPfenex Inc (PFNX) Announces Earnings Results - March 16 at 10:43 AM logoPfenex Reports Fourth Quarter and Full Year 2016 Results and Provides Business Update - March 15 at 7:23 PM logoQ4 2016 Pfenex Inc Earnings Release - After Market Close - March 15 at 9:26 AM logoPfenex Inc (PFNX) to Release Quarterly Earnings on Wednesday - March 14 at 8:31 AM logoPfenex To Report Fourth Quarter and Full Year 2016 Results and Provide Business Update on Wednesday, March 15, 2017 - March 1 at 10:02 AM logoPfenex Inc. to Participate in Panel Discussion at 2017 BIO CEO & Investor Conference - February 10 at 8:11 PM logo8:02 am Pfenex announced that Dr. Bertrand C. Liang has resigned his position as CEO, President, Secretary and as a member of the Board of Directors of the Co - January 24 at 7:57 PM logoPfenex Announces Leadership Transition - January 24 at 8:37 AM logoPFENEX INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Other Events, Fi - January 24 at 8:37 AM logoPfenex (PFNX) Catches Eye: Stock Adds 6.6% in Session - November 17 at 10:45 AM logoForm 4 Pfenex Inc. For: Nov 15 Filed by: Lucy Patrick K. - November 16 at 7:05 PM logoPfenex Reports Third Quarter 2016 Results and Provides Business Update - November 10 at 9:55 AM logoEdited Transcript of PFNX earnings conference call or presentation 9-Nov-16 9:30pm GMT - November 10 at 9:55 AM logoQ3 2016 Pfenex Inc Earnings Release - After Market Close - November 9 at 9:24 AM logoPfenex To Report Third Quarter 2016 Results and... - October 26 at 6:49 PM


This page was last updated on 9/21/2017 by Staff